#2-62E. Quantifying APS Activity: Introducing the EULAR Disease Activity Score (ARD, 2025)

Antiphospholipid Syndrome (APS) presents significant clinical challenges, especially the lack of a standardized measure to objectively capture the activity of its diverse thrombotic, microvascular, and non-thrombotic manifestations, thereby hindering treatment monitoring and clinical trial development. This paper details the rigorous, consensus-based methodology used to develop the European Alliance of Associations for Rheumatology (EULAR) APS Disease Activity Score (EAPSDAS). The EAPSDAS consists of two validated, independent scales: one for TMN (Thrombotic/Microvascular/Nonthrombotic) manifestations and a separate Obstetric scale67. The most critical finding is the establishment of this novel, quantitative EULAR score, which uses real-world vignettes and physician global assessment (PhysGA) to assign weighted scores to new or worsening manifestations, effectively creating a unified metric for disease activity. This score is highly relevant to clinicians as it provides a robust endpoint for trials of new therapies and offers a structured approach for monitoring patients and assessing treatment response in daily practice. However, users must be aware that while initial validation was performed, the authors explicitly state that further validation in prospective, multicenter cohorts is required.

Citation: Maria G. Tektonidou, et al. Development and validation of a EULAR disease activity score in antiphospholipid syndrome. Annals of the Rheumatic Diseases. 2025. DOI: 10.1016/j.ard.2025.10.0061314.

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.